Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REZILIENT5 platform study of zipalertinib in EGFR-mutant non-small cell lung cancer
jRCT2051250013Recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of zipalertinib in non-small cell lung cancer (NSCLC) (6 cohorts), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Incidence of dose-limiting toxicities and Objective response rate. Started Jun 2025; status: recruiting.
02
Drugs
zipalertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051250013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250013.